[go: up one dir, main page]

MX2018000599A - Compuesto heterociclico que contiene nitrogeno. - Google Patents

Compuesto heterociclico que contiene nitrogeno.

Info

Publication number
MX2018000599A
MX2018000599A MX2018000599A MX2018000599A MX2018000599A MX 2018000599 A MX2018000599 A MX 2018000599A MX 2018000599 A MX2018000599 A MX 2018000599A MX 2018000599 A MX2018000599 A MX 2018000599A MX 2018000599 A MX2018000599 A MX 2018000599A
Authority
MX
Mexico
Prior art keywords
nitrogen
heterocyclic compound
containing heterocyclic
cxcl10
halogen atom
Prior art date
Application number
MX2018000599A
Other languages
English (en)
Inventor
Tanaka Tadashi
Fujino Masataka
Furuya Kentaro
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of MX2018000599A publication Critical patent/MX2018000599A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Un compuesto representado por la fórmula general, o una sal del mismo, tiene una actividad inhibidora de CXCL10 excepcional y es útil como un agente de tratamiento para la prevención y/o tratamiento, etc., de enfermedades que implican la sobreproducción de CXCL10. En la fórmula: R1 es un grupo alquilo de 1 a 6 átomos de carbono, etc.; R2 es un átomo de hidrógeno, etc.; R3 es un átomo de halógeno, etc.; Z1, Z2 y Z3 son CH, etc.; X1 es CONH, etc.; el anillo A es un grupo fenilo, etc.; R4 es un átomo de halógeno, etc.; y m es un número entero de 0-5. (ver Fórmula).
MX2018000599A 2015-07-17 2016-07-15 Compuesto heterociclico que contiene nitrogeno. MX2018000599A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015143503 2015-07-17
JP2016019782 2016-02-04
PCT/JP2016/071047 WO2017014201A1 (ja) 2015-07-17 2016-07-15 含窒素複素環化合物

Publications (1)

Publication Number Publication Date
MX2018000599A true MX2018000599A (es) 2018-05-28

Family

ID=57834388

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000599A MX2018000599A (es) 2015-07-17 2016-07-15 Compuesto heterociclico que contiene nitrogeno.

Country Status (16)

Country Link
US (1) US10696637B2 (es)
EP (1) EP3327004B1 (es)
JP (1) JP6734277B2 (es)
KR (1) KR20180026774A (es)
CN (1) CN108137505B (es)
AU (1) AU2016297037B9 (es)
BR (1) BR112018000925A2 (es)
CA (1) CA2992698A1 (es)
HK (1) HK1249105A1 (es)
IL (1) IL256765A (es)
MX (1) MX2018000599A (es)
RU (1) RU2720205C2 (es)
SG (1) SG11201800445PA (es)
TW (1) TWI701241B (es)
WO (1) WO2017014201A1 (es)
ZA (1) ZA201800967B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102271111B1 (ko) 2016-12-27 2021-06-29 후지필름 가부시키가이샤 항종양제 및 브로모도메인 저해제
CN111630099B (zh) * 2018-12-27 2021-04-20 株式会社Adeka 聚烯烃系树脂用成核剂、含有其的聚烯烃系树脂用成核剂组合物、聚烯烃系树脂组合物
AR130477A1 (es) * 2022-09-14 2024-12-11 Vanqua Bio Inc Antagonistas de c5ar1 y sus usos

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06502845A (ja) * 1990-09-07 1994-03-31 シェリング・コーポレーション 抗ウイルス化合物および抗高血圧化合物
JPH0673011A (ja) * 1992-07-02 1994-03-15 Sawai Seiyaku Kk カルボスチリル誘導体および抗アレルギー剤
US5457099A (en) 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
JP2000256323A (ja) * 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
AU9384701A (en) 2000-10-02 2002-04-15 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
ATE325116T1 (de) * 2000-12-27 2006-06-15 Janssen Pharmaceutica Nv Farnesyltransferasehemmende 4- heterocyclylchinolin- und chinazolinderivate
ATE319704T1 (de) * 2000-12-27 2006-03-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
WO2003053926A1 (en) * 2001-12-13 2003-07-03 Ajinomoto Co.,Inc. Novel phenylalanine derivative
AU2003259117A1 (en) * 2002-07-10 2004-01-23 The Regents Of The University Of California Antimicrobial activity of interferon-inducible elr chemokines
CN1774247A (zh) * 2003-02-14 2006-05-17 史密丝克莱恩比彻姆公司 新的化合物
US7816372B2 (en) 2003-08-22 2010-10-19 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
EP1954274B8 (en) * 2005-11-10 2011-01-12 ChemoCentryx, Inc. Substituted quinolones and methods of use
JP2010280569A (ja) * 2007-09-25 2010-12-16 Jimro Co Ltd Ｃｘｃｌ１０産生抑制剤
EP2239264A4 (en) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMORAL MEDIUM
US20100016338A1 (en) * 2008-07-21 2010-01-21 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents
WO2010017355A2 (en) * 2008-08-08 2010-02-11 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
KR20110048571A (ko) 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
NZ596488A (en) 2009-06-26 2012-11-30 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
HK1222793A1 (zh) 2013-03-14 2017-07-14 康威基内有限公司 用於抑制含布罗莫结构域的蛋白质的方法和组合物
ES2896400T3 (es) 2014-08-01 2022-02-24 Nuevolution As Compuestos activos frente a bromdominios
US20190092761A1 (en) 2014-11-13 2019-03-28 Convergene Llc Methods and Compositions for Inhibition of Bromodomain and Extratermial Proteins
KR102271111B1 (ko) 2016-12-27 2021-06-29 후지필름 가부시키가이샤 항종양제 및 브로모도메인 저해제

Also Published As

Publication number Publication date
TW201713622A (zh) 2017-04-16
AU2016297037A1 (en) 2018-02-15
RU2018105867A (ru) 2019-08-20
RU2720205C2 (ru) 2020-04-27
TWI701241B (zh) 2020-08-11
US10696637B2 (en) 2020-06-30
CN108137505B (zh) 2021-07-06
AU2016297037B2 (en) 2020-07-02
JPWO2017014201A1 (ja) 2018-06-07
US20190077761A1 (en) 2019-03-14
KR20180026774A (ko) 2018-03-13
SG11201800445PA (en) 2018-02-27
EP3327004A4 (en) 2019-03-27
RU2018105867A3 (es) 2019-12-19
JP6734277B2 (ja) 2020-08-05
CN108137505A (zh) 2018-06-08
AU2016297037B9 (en) 2020-10-29
HK1249105A1 (zh) 2018-10-26
ZA201800967B (en) 2019-06-26
IL256765A (en) 2018-03-29
CA2992698A1 (en) 2017-01-26
EP3327004B1 (en) 2020-11-04
BR112018000925A2 (pt) 2018-09-11
EP3327004A1 (en) 2018-05-30
WO2017014201A1 (ja) 2017-01-26

Similar Documents

Publication Publication Date Title
MY177250A (en) Novel nicotinamide derivative or salt thereof
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
MY169043A (en) New dihydroquinoline-2-one derivatives
MX351812B (es) Derivados de piridona.
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MY186165A (en) New bicyclic dihydroquinoline-2-one derivatives
MX352928B (es) Compuestos de piridazina-amida.
MX2014002208A (es) Inhibidores de serina/treonina quinasa.
MY194307A (en) Pyridone derivative having tetrahydropyranylmethyl group
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
MY169267A (en) New aryl-quinoline derivatives
IN2014DN07509A (es)
PH12017500095A1 (en) Imidazopyridazine compounds
MX2016007861A (es) Compuestos de ácido dimetilbenzoico.
PH12015502429A1 (en) Dicarboxylic acid compound
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
JO3318B1 (ar) مثبطات bace
MX2018005133A (es) Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos.
PH12018502012B1 (en) Griseofulvin compound
MX2018001317A (es) Inhibidores del virus sincitial respiratorio.
SG11201810725WA (en) Novel β-lactamase inhibitors
MX2018000599A (es) Compuesto heterociclico que contiene nitrogeno.
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.